Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Company Overview

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $0.32 to $0.34
• 50-Day Range: $0.20 to $0.21
• 52-Week Range: $0.20 to $0.75
• Volume: 3.93 million shs
• Average Volume: 915,302 shs
• Market Capitalization: $7.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYTX Stock Analysis - Frequently Asked Questions

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) announced its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.

When did Cytori Therapeutics' stock split?

Cytori Therapeutics's stock reverse split on the morning of Thursday, May 24th 2018.The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU).

Company Calendar

• Last Earnings: 5/14/2019
• Today: 7/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & Medical Instruments
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CYTX
• CIK: 1095981
• Web: www.cytori.com
• Phone: 858-458-0900
• Fax: N/A
• Employees: 37
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.63 million
• Net Margins: -242.60%
• Pretax Margin: N/A
• Return on Equity: -272.70%
• Return on Assets: -56.23%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 0.46
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $3.67 million
• Price / Sales: 1.96
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 22,160,000
• Free Float: N/A
• Market Cap: $7.18 million
• Optionable: Not Optionable
• Beta: 1.96